All In Biotech

Drug Trial Radar · NCT06834347

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 231 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

231

Actual

Start

Feb 12, 2025

Primary completion

Sep 23, 2026

Study completion Mar 26, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Feb 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

EFC18418 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study with 3 treatment groups. The purpose of the study is to evaluate the efficacy, safety and tolerability of 2 dosing regimens of itepekimab compared to placebo as add-on therapy to intranasal corticosteroids (INCS) in male and female participants with chronic rhinosinusitis with nasal polyps (CRSwNP) aged 18 years of age and older. Study details include: * The study duration per participant (4-week screening, 52-week treatment, 20-week safety follow-up) will be up to 76 weeks. For participants transitioning to the LTS18420 study, the study duration will be 56 weeks. * The treatment duration will be up to 52 weeks. * The number of visits will be 9 site visits and 20 phone/home visits.

Conditions

  • Chronic Rhinosinusitis With Nasal Polyps

Interventions

  • Itepekimab (SAR440340)Drug

    Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous

  • PlaceboDrug

    Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous

  • Mometasone furoate nasal spray (MFNS)Drug

    Pharmaceutical form: Solution for administration via spray pump. Route of administration: Intranasal spray

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the endoscopic NPSTime frame: Baseline to Week 24
  2. Change from baseline in the NCSTime frame: Baseline to Week 24

Locations

121 sites in 21 countries. Site status is shown where the registry gives one.

  • University of Southern California (USC) / Keck Medicine of USC- Site Number : 8400037

    Arcadia, California

  • Sensa Health- Site Number : 8400038

    Los Angeles, California

  • Newport Native MD- Site Number : 8400031

    Newport Beach, California

  • Sacramento Ear Nose & Throat - Roseville- Site Number : 8400064

    Roseville, California

  • Breathe Clear Institute of Sinus and Allergy Relief- Site Number : 8400040

    Torrance, California

  • Orso Health - Torrance - Hawthorne Boulevard- Site Number : 8400035

    Torrance, California

  • Advanced Research Associates (ARA) Professionals- Site Number : 8400011

    Miami, Florida

  • Paradisus Med Research - Miami- Site Number : 8400009

    Miami, Florida

  • Orlando ENT Associates - Orlando- Site Number : 8400008

    Orlando, Florida

  • Emory University School of Medicine- Grady Campus- Site Number : 8400047

    Atlanta, Georgia

  • Treasure Valley Medical Research- Site Number : 8400063

    Boise, Idaho

  • University of Chicago Medical Center- Site Number : 8400018

    Chicago, Illinois

  • Deaconess Clinic Allergy East- Site Number : 8400056

    Evansville, Indiana

  • SSM Health Saint Louis University Hospital- Site Number : 8400005

    St Louis, Missouri

  • Northwell Health Physician Partners Rheumatology at Great Neck- Site Number : 8400028

    Great Neck, New York

  • Essential Medical Research- Site Number : 8400066

    Tulsa, Oklahoma

  • TEN20 Clinical Research - Dallas- Site Number : 8400015

    Dallas, Texas

  • Houston Methodist Hospital- Site Number : 8400054

    Houston, Texas

  • ENT Associates of Texas - McKinne- Site Number : 8400062

    McKinney, Texas

  • Alamo ENT Associates- Site Number : 8400065

    San Antonio, Texas

  • Eastern Virginia Medical School (EVMS) Medical Group- Site Number : 8400046

    Norfolk, Virginia

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina

  • Investigational Site Number : 0320005

    Buenos Aires, Argentina

  • Investigational Site Number : 0320003

    Mendoza, Argentina

  • Investigational Site Number : 0320002

    La Plata, Buenos Aires, Argentina

  • Investigational Site Number : 0320004

    Rosario, Santa Fe Province, Argentina

  • Investigational Site Number : 0400005

    Graz, Austria

  • Investigational Site Number : 0400002

    Linz, Austria

  • Investigational Site Number : 0400001

    Vienna, Austria

  • Hospital Israelita Albert Einstein- Site Number : 0760001

    São Paulo, Brazil

  • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760002

    Ribeirão Preto, São Paulo, Brazil

  • Centro Internacional de Pesquisa Clínica (CIPES)- Site Number : 0760005

    São José dos Campos, São Paulo, Brazil

  • Investigational Site Number : 1240005

    London, Ontario, Canada

  • Investigational Site Number : 1240002

    Montreal, Quebec, Canada

  • Investigational Site Number : 1240001

    Québec, Quebec, Canada

  • Investigational Site Number : 1520006

    Valdivia, Los Ríos Region, Chile

  • Investigational Site Number : 1520003

    Talca, Maule Region, Chile

  • Investigational Site Number : 1520004

    Lo Barnechea, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520002

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, Chile

Showing 40 of 121 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.